<DOC>
	<DOC>NCT00303056</DOC>
	<brief_summary>The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief relative to triamcinolone, to evaluate the safety of icatibant, to evaluate overall conditions of daily life after treatment with icatibant, to assess systemic exposure of icatibant following intra-articular injection.</brief_summary>
	<brief_title>Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis</brief_title>
	<detailed_description>This is a multinational, randomized, placebo-controlled study to be conducted in Europe and the US. Study medication will be administered by intra-articular injection 3 times in weekly intervals, being followed by an observation period of further 11 weeks.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<criteria>Male and female subjects with painful osteoarthritis of the knee. Subjects presenting with diagnosis of OA &lt; 3 months and an OA grading &lt; K&amp;L grade II, with any condition with impact on on the target indication, any testcompoundrelated condition, any studyrelated condition (all those conditions detailled in the CSP).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>knee</keyword>
</DOC>